KR102092744B1 - 인간화된 ＦｃγＲ 마우스 - Google Patents

인간화된 ＦｃγＲ 마우스 Download PDF

Info

Publication number
KR102092744B1
KR102092744B1 KR1020197011653A KR20197011653A KR102092744B1 KR 102092744 B1 KR102092744 B1 KR 102092744B1 KR 1020197011653 A KR1020197011653 A KR 1020197011653A KR 20197011653 A KR20197011653 A KR 20197011653A KR 102092744 B1 KR102092744 B1 KR 102092744B1
Authority
KR
South Korea
Prior art keywords
human
mouse
chain
fcγr
low affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197011653A
Other languages
English (en)
Korean (ko)
Other versions
KR20190045404A (ko
Inventor
린 맥도날드
나씬 투
카간 구러
션 스티븐스
앤드류 제이 머피
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102092744(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20190045404A publication Critical patent/KR20190045404A/ko
Application granted granted Critical
Publication of KR102092744B1 publication Critical patent/KR102092744B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
KR1020197011653A 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스 Active KR102092744B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
US61/288,562 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187014568A Division KR101973524B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007903A Division KR102178064B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스

Publications (2)

Publication Number Publication Date
KR20190045404A KR20190045404A (ko) 2019-05-02
KR102092744B1 true KR102092744B1 (ko) 2020-03-24

Family

ID=43601078

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197011653A Active KR102092744B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스
KR1020207007903A Active KR102178064B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스
KR1020127019435A Active KR101862277B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스
KR1020187014568A Active KR101973524B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207007903A Active KR102178064B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스
KR1020127019435A Active KR101862277B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스
KR1020187014568A Active KR101973524B1 (ko) 2009-12-21 2010-12-17 인간화된 ＦｃγＲ 마우스

Country Status (27)

Country Link
US (9) US8658154B2 (enExample)
EP (4) EP3336102A3 (enExample)
JP (4) JP5595517B2 (enExample)
KR (4) KR102092744B1 (enExample)
CN (2) CN104232589B (enExample)
AU (3) AU2010339863B2 (enExample)
CA (2) CA3000246C (enExample)
CY (1) CY1120316T1 (enExample)
DK (2) DK2516457T3 (enExample)
ES (2) ES3062012T3 (enExample)
FI (1) FI3498730T3 (enExample)
HK (1) HK1257001A1 (enExample)
HR (2) HRP20260349T1 (enExample)
HU (1) HUE038684T2 (enExample)
IL (4) IL220365A (enExample)
LT (2) LT2516457T (enExample)
MY (1) MY156743A (enExample)
NO (1) NO2516457T3 (enExample)
PL (2) PL3498730T3 (enExample)
PT (2) PT2516457T (enExample)
RS (2) RS67844B1 (enExample)
RU (1) RU2549695C2 (enExample)
SG (3) SG10201408415PA (enExample)
SI (2) SI2516457T1 (enExample)
SM (2) SMT201800296T1 (enExample)
TR (1) TR201808011T4 (enExample)
WO (1) WO2011084664A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2516457T3 (enExample) 2009-12-21 2018-08-11
PL2818478T3 (pl) 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
JP2014532399A (ja) * 2011-11-01 2014-12-08 ロシュ グリクアート アーゲー インビボａｄｃｃモデル
ES2884598T3 (es) * 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
CN106255410B (zh) * 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
RU2700484C2 (ru) * 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
AU2015266841C1 (en) 2014-05-30 2018-06-07 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase IV (DPP4) animals
EP3808775B1 (en) * 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
WO2016175285A1 (ja) * 2015-04-30 2016-11-03 株式会社特殊免疫研究所 ヒト特定分子およびヒトＦｃγ受容体ファミリーを発現するトランスジェニック非ヒト動物
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
EP3861854B1 (en) * 2018-09-27 2025-01-22 Central Institute for Experimental Medicine and Life Science Immunodeficient mouse
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
US20220192166A1 (en) * 2019-03-28 2022-06-23 Central Institute For Experimental Animals Immunodeficient rodent
AU2021400584A1 (en) * 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4287828A4 (en) * 2021-02-02 2025-01-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028959A1 (en) * 1994-04-22 1995-11-02 Sloan-Kettering Institute For Cancer Research MICE MUTANT FOR Fc RECEPTORS AND METHOD OF TREATING AUTOIMMUNE DISEASE
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011490A1 (en) * 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US7413031B2 (en) 2000-07-18 2008-08-19 The Charles Machine Works, Inc. Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) * 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003233246B2 (en) 2002-06-07 2008-04-10 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd FcyRIIa transgenic animal model for autoimmune disease
JP2004147535A (ja) * 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
JP2006517096A (ja) 2002-12-16 2006-07-20 ジェネンテック・インコーポレーテッド ヒトｃｄ２０を発現するトランスジェニックマウス
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US20070148170A1 (en) * 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
EP1706424B1 (en) * 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
JP5401314B2 (ja) * 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
AU2008335178A1 (en) * 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
WO2010010549A2 (en) * 2008-07-23 2010-01-28 Rappaport Family Institute For Research In The Medical Sciences Methods of altering peripheral b cell populations and uses thereof
NO2516457T3 (enExample) 2009-12-21 2018-08-11
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1995028959A1 (en) * 1994-04-22 1995-11-02 Sloan-Kettering Institute For Cancer Research MICE MUTANT FOR Fc RECEPTORS AND METHOD OF TREATING AUTOIMMUNE DISEASE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human Mutation, Vol. 30, No. 5, pp. E640-650 (온라인 공개일: 2009.03.23.)

Also Published As

Publication number Publication date
US20240424145A1 (en) 2024-12-26
KR20190045404A (ko) 2019-05-02
JP2014132909A (ja) 2014-07-24
IL242719A (en) 2017-09-28
SMT201800296T1 (it) 2018-07-17
RU2012131296A (ru) 2014-01-27
MY156743A (en) 2016-03-31
KR20200033981A (ko) 2020-03-30
US20200061213A1 (en) 2020-02-27
US20150313195A1 (en) 2015-11-05
EP4706388A2 (en) 2026-03-11
SI3498730T1 (sl) 2026-03-31
US8658853B2 (en) 2014-02-25
HRP20180911T1 (hr) 2018-07-13
US12036288B2 (en) 2024-07-16
SG10202011814TA (en) 2021-01-28
IL220365A (en) 2016-11-30
US20140154701A1 (en) 2014-06-05
AU2010339863A1 (en) 2012-07-12
JP5891259B2 (ja) 2016-03-22
CA2784953C (en) 2018-05-22
KR101862277B1 (ko) 2018-06-01
KR20180058860A (ko) 2018-06-01
US8658154B2 (en) 2014-02-25
CA3000246A1 (en) 2011-07-14
EP3498730A1 (en) 2019-06-19
RS67844B1 (sr) 2026-03-31
EP2516457A1 (en) 2012-10-31
KR20120102138A (ko) 2012-09-17
HUE038684T2 (hu) 2018-11-28
CY1120316T1 (el) 2019-07-10
CN102762590A (zh) 2012-10-31
AU2010339863B2 (en) 2014-07-17
EP2516457B9 (en) 2021-09-29
US20120260357A1 (en) 2012-10-11
US20140157445A1 (en) 2014-06-05
IL261257A (en) 2018-10-31
CA2784953A1 (en) 2011-07-14
RU2549695C2 (ru) 2015-04-27
US20110154512A1 (en) 2011-06-23
AU2014210646A1 (en) 2014-08-28
SG10201408415PA (en) 2015-01-29
ES2671188T3 (es) 2018-06-05
AU2014210646B2 (en) 2016-06-23
SI2516457T1 (en) 2018-08-31
CN104232589A (zh) 2014-12-24
RS57280B1 (sr) 2018-08-31
JP5595517B2 (ja) 2014-09-24
CA3000246C (en) 2021-05-25
EP3498730B1 (en) 2026-01-28
AU2014210645A1 (en) 2014-08-28
DK2516457T3 (en) 2018-06-18
JP6073840B2 (ja) 2017-02-01
HK1257001A1 (en) 2019-10-11
US20210346522A1 (en) 2021-11-11
DK3498730T3 (da) 2026-02-23
FI3498730T3 (fi) 2026-03-12
AU2014210645B2 (en) 2016-05-19
PL2516457T3 (pl) 2018-08-31
SG181690A1 (en) 2012-07-30
HRP20260349T1 (hr) 2026-04-24
US9089599B2 (en) 2015-07-28
US9056130B2 (en) 2015-06-16
CN102762590B (zh) 2015-11-25
CN104232589B (zh) 2018-04-27
US20180015185A1 (en) 2018-01-18
EP3336102A2 (en) 2018-06-20
US10426848B2 (en) 2019-10-01
PL3498730T3 (pl) 2026-04-07
US11020495B2 (en) 2021-06-01
IL220365A0 (en) 2012-08-30
PT3498730T (pt) 2026-02-18
JP2016093201A (ja) 2016-05-26
SMT202600074T1 (it) 2026-03-09
WO2011084664A1 (en) 2011-07-14
KR101973524B1 (ko) 2019-09-02
KR102178064B1 (ko) 2020-11-12
PT2516457T (pt) 2018-06-12
LT3498730T (lt) 2026-03-25
JP2014209923A (ja) 2014-11-13
JP2013514778A (ja) 2013-05-02
TR201808011T4 (tr) 2018-06-21
US9687566B2 (en) 2017-06-27
IL261257B (en) 2019-12-31
NO2516457T3 (enExample) 2018-08-11
IL271083A (en) 2020-01-30
LT2516457T (lt) 2018-06-11
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
ES3062012T3 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
US20240424145A1 (en) LOW AFFINITY FcyR DEFICIENT MICE
US9221894B2 (en) Isolated cells from humanized FcγR mice
HK40009391A (en) Humanized fc gamma r mice
HK1171033B (en) Humanized fc gamma r mice
HK1171033A (en) Humanized fc gamma r mice

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190423

Application number text: 1020187014568

Filing date: 20180523

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190522

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190604

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191219

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200319

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240226

Start annual number: 5

End annual number: 5